Received Feb 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | 1 | — | — |
Heplisav-B Given After Starting A Three Dose Hep-B Series; Incomplete Course of Vaccination; Initial report received on 28-Jan-2025. A pharmacist reported that a female (age and race not provided) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization after starting a three dose hepatitis B series. The patient has not received the second dose as of date of report. No medical history or concomitant medications were reported. On an unknown date, the patient received an unknown dose of a three-dose hepatitis B vaccine (brand name and lot number not provided). In Oct-2024, after receiving a dose of an unknown three-dose hepatitis B vaccine, the patient received a dose of a hepatitis B vaccine HEPLISAV-B (lot number, expiration date, NDC number, route, and site not available). At the time of report, the patient has not received the second dose or HEPLISAV-B yet. No adverse reactions were reported. The reporter declined to provide further information. Company Comment: The company assessed the events as non-serious.; Sender's Comments: The company assessed the events as non-serious.